$17.06
1.19% day before yesterday
Nasdaq, Nov 21, 10:00 pm CET
ISIN
IL0011316309
Symbol
MDWD

MediWound Ltd. Stock price

$17.06
-1.59 8.50% 1M
-2.83 14.23% 6M
-0.74 4.16% YTD
+0.30 1.79% 1Y
+6.49 61.40% 3Y
-8.77 33.95% 5Y
-50.63 74.80% 10Y
-103.83 85.89% 20Y
Nasdaq, Closing price Fri, Nov 21 2025
+0.20 1.19%
ISIN
IL0011316309
Symbol
MDWD
Industry

Key metrics

Basic
Market capitalization
$218.7m
Enterprise Value
$194.4m
Net debt
positive
Cash
$32.4m
Shares outstanding
10.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.0 | 8.9
EV/Sales
9.8 | 7.9
EV/FCF
negative
P/B
10.9
Financial Health
Equity Ratio
42.4%
Return on Equity
-97.0%
ROCE
-58.3%
ROIC
-404.1%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$19.9m | $24.5m
EBITDA
$-20.6m | $-32.2m
EBIT
$-22.1m | $-23.9m
Net Income
$-28.0m | $-30.5m
Free Cash Flow
$-19.3m
Growth (TTM | estimate)
Revenue
-1.4% | 21.4%
EBITDA
-50.3% | -73.7%
EBIT
-46.2% | -23.3%
Net Income
-39.9% | -1.1%
Free Cash Flow
13.5%
Margin (TTM | estimate)
Gross
18.4%
EBITDA
-103.8% | -131.3%
EBIT
-111.4%
Net
-140.8% | -124.4%
Free Cash Flow
-97.0%
More
EPS
$-2.6
FCF per Share
$-1.8
Short interest
9.0%
Employees
111
Rev per Employee
$180.0k
Show more

Is MediWound Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

MediWound Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a MediWound Ltd. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a MediWound Ltd. forecast:

Buy
92%
Hold
8%

Financial data from MediWound Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
20 20
1% 1%
100%
- Direct Costs 16 16
7% 7%
82%
3.66 3.66
37% 37%
18%
- Selling and Administrative Expenses 14 14
23% 23%
70%
- Research and Development Expense 12 12
77% 77%
60%
-21 -21
50% 50%
-104%
- Depreciation and Amortization 1.51 1.51
7% 7%
8%
EBIT (Operating Income) EBIT -22 -22
46% 46%
-111%
Net Profit -28 -28
40% 40%
-141%

In millions USD.

Don't miss a Thing! We will send you all news about MediWound Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediWound Ltd. Stock News

Neutral
Seeking Alpha
3 days ago
MediWound Ltd. ( MDWD ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Joshua Jennings - TD Cowen, Research Division Swayampakula Ramakanth - H.C.
Neutral
GlobeNewsWire
3 days ago
Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid ® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Million Equity Financing Third Quarter 2025 Revenue of $5.4 Million, Up 23% Year-over-Year Conference Call Today, November 20, 2025, at 8:30 a.m. Eastern Time YAV...
Neutral
GlobeNewsWire
18 days ago
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd.
More MediWound Ltd. News

Company Profile

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Head office Israel
CEO Ofer Gonen
Employees 111
Founded 2000
Website www.mediwound.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today